Related Experiment Video
Updated: Aug 29, 2026

Isolation, Transfection, and Culture of Primary Human Monocytes
Published on: December 16, 2019
Cardiovascular disease in patients infected with the human immunodeficiency virus
Enrique M Velasquez1, D Luke Glancy
1Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, USA.
Insights
Cardiovascular issues are rising in human immunodeficiency virus (HIV) patients due to longer lifespans and treatments. Highly active antiretroviral therapy (HAART) improves outcomes but may accelerate cardiovascular disease.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- Global human immunodeficiency virus (HIV) infections are increasing, with improved treatments leading to longer patient survival.
- This increased longevity results in a higher prevalence of cardiovascular manifestations, often appearing later in the course of HIV infection.
Purpose of the Study:
- To review the spectrum of cardiovascular manifestations in HIV-infected individuals.
- To discuss the impact of highly active antiretroviral therapy (HAART) on cardiovascular health in HIV patients.
Main Methods:
- Literature review of cardiovascular complications in HIV infection.
- Analysis of the effects of HAART, including protease inhibitors, on cardiovascular disease risk factors.
Main Results:
- Pericardial effusion is the most common cardiovascular manifestation, typically small and asymptomatic, but indicative of a poor prognosis.
- Other serious cardiovascular conditions include myocarditis, dilated cardiomyopathy, pulmonary arterial hypertension, cardiac lymphoma, and Kaposi's sarcoma.
- HAART improves overall prognosis but is associated with lipodystrophy and accelerated atherosclerotic cardiovascular disease, including glucose intolerance, diabetes, dyslipidemia, and elevated lipoprotein (a).
Conclusions:
- Cardiovascular disease is a significant and growing concern for HIV-infected individuals.
- While HAART is crucial for managing HIV, its role in accelerating cardiovascular disease requires careful monitoring and management strategies.
Abstract:
Worldwide, infection with the human immunodeficiency virus (HIV) is increasing. At the same time, new treatments allow patients to live longer. Consequently, cardiovascular manifestations, most of which occur relatively late in the course of the infection, are becoming more frequent. Pericardial effusion, the most common cardiovascular manifestation of HIV infection, usually is small and causes no hemodynamic compromise or symptoms. It does, however, augur a grim prognosis, as do other cardiovascular conditions associated with the infection: myocarditis, dilated cardiomyopathy, pulmonary arterial hypertension, cardiac lymphoma, and Kaposi's sarcoma of the heart. Highly active antiretroviral therapy (HAART), especially when incorporating protease inhibitors, greatly improves overall outlook in these patients, but appears not only to cause a lipodystrophic syndrome, but to accelerate atherosclerotic cardiovascular disease by inducing glucose intolerance, frank diabetes mellitus, hypertriglyceridemia, hypercholesterolemia, increased lipoprotein (a), and decreased HDL cholesterol. Recent ongoing prospective trials also are showing an association of HAART with increased coronary artery disease and myocardial infarction.
Related Concept Videos
Sexually Transmitted Infections
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Cryptococcal Meningitis
Myocarditis III: Medical Management
Cytomegalovirus Disease
